Optison records modest growth for MBI
The long-term potential of ultrasound contrast agents may be great, but ultrasound practitioners appear to be taking a measured approach to the technology, if the third-quarter financial results of Molecular Biosystems are any indication. The San Diego
The long-term potential of ultrasound contrast agents may be great, but ultrasound practitioners appear to be taking a measured approach to the technology, if the third-quarter financial results of Molecular Biosystems are any indication. The San Diego ultrasound contrast developer this month released financial results for the quarter (end-September) that show only a slight increase in sales of its Optison contrast agent.
For the period, MBI had product and royalty revenues of $1.41 million, most of which were Optison sales. This compares with product and royalty revenues of $1.37 million in the second quarter of 1998. MBI and marketing partner Mallinckrodt of St. Louis launched Optison in January.
MBI recorded total third-quarter revenues of $2.7 million, compared with sales of $1.4 million in the third quarter of 1997. The company posted a net loss of $7.1 million in the most recent period, compared with a loss of $4.6 million in the same period a year ago.
MBI president and CEO Bobba Venkatadri acknowledged that sales of Optison are growing at a modest pace, but he said the company remains confident in the agents long-term potential. Shares of MBI fell 13% to close at $3.38 on Oct. 21, the day the news was announced.
Considering Breast- and Lesion-Level Assessments with Mammography AI: What New Research Reveals
June 27th 2025While there was a decline of AUC for mammography AI software from breast-level assessments to lesion-level evaluation, the authors of a new study, involving 1,200 women, found that AI offered over a seven percent higher AUC for lesion-level interpretation in comparison to unassisted expert readers.
